- |||||||||| Review, Journal: Emerging Immunotherapy for Acute Myeloid Leukemia. (Pubmed Central) - Apr 27, 2021
The current advantages of IO therapy in the field of AML are summarized herein. However, although cancer vaccination should be included in the concept of IO therapy, it is not mentioned in this review because of the paucity of relevant evidence.
- |||||||||| Review, Journal: Sialometabolism in Brain Health and Alzheimer's Disease. (Pubmed Central) - Apr 21, 2021
In summary, this article reviews current understanding of neural functions of sialic acids and alterations of sialometabolism in aging and AD brains. Furthermore, we discuss the possibility of looking at sialic acids as a promising novel therapeutic target for AD intervention.
- |||||||||| Dendritic and myeloid suppressor cellsas immunosuppressive biomarkers in sepsis () - Apr 20, 2021 - Abstract #EAACI2021EAACI_671;
A study of the content of M-MLSCs and G-MLSCs with the CD33 + phenotype showed no significant differences between controls and patients with sepsis and septic shock. Conclusion The percentage levels of pDC, mDC and G-MLSCs of CD15+ may be useful as a quantitative indicator of immunosuppression in sepsis and septic shock patients.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
[VIRTUAL] VENETOCLAX AND LIPOSOMAL CYTARABINE-DAUNORUBICIN IN REFRACTORY AMKL WITH CBFA2T3-GLIS2 FUSION () - Apr 14, 2021 - Abstract #ASPHO2021ASPHO_486;
Innovative solutions are desperately needed for this grave disease. Assessing Bcl-2 status and incorporating venetoclax and liposomal daunorubicin- cytarabine into initial therapeutic planning should be strongly considered in these patients.
- |||||||||| Preclinical, Review, Journal: Preclinical and linical in himeric Antigen Receptor Therapy for ematological alignancies. (Pubmed Central) - Apr 10, 2021
In addition to the most widely applied target, namely, CD19, researchers have further explored the possibility of other targets, such as CD20, CD22, CD33, and CD123, and have tested a series of combination antigen CAR T-cell therapies. Here, we summarize the current preclinical and clinical studies of dual-target CAR T-cells.
- |||||||||| Review, Journal: Understanding stem cells and its pivotal role in regenerative medicine. (Pubmed Central) - Apr 10, 2021
The biomarkers that are mentioned in various literatures and experiments include PDX1, FOXA2, HNF6, and NKX6-1 (for diabetes); CD33, CD24, CD133 (for cancer); c-Kit, SCA-1, Wilm's tumor 1 (for cardiovascular disorders); and OCT4, SOX2, c-MYC, EN1, DAT and VMAT2 (for neurological disorders). In this review, we come to know the advancements and scopes of potential SC-based therapies, its diverse applications in clinical fields that can be helpful in the near future.
- |||||||||| Journal, PD(L)-1 Biomarker: Integrative Analysis of the Expression of SIGLEC Family Members in Lung Adenocarcinoma via Data Mining. (Pubmed Central) - Apr 7, 2021
Furthermore, we found that SIGLEC expression was significantly correlated with immune-cell infiltration, especially macrophages, neutrophils, and dendritic cells, and highly associated with immune molecules such as CD80, CD86, CD28, B-cell-activating factor, programmed cell death 1 ligand 2, and colony stimulating factor 1 receptor. These results provide insight into the potential molecular mechanism associated with SIGLEC-related development of LUAD, as well as clues for screening biomarkers and therapeutic targets.
- |||||||||| [VIRTUAL] Abstract Presentation: Aggressive Thyroid Cancer is Associated With Suppressor Circulating Immunophenotype () - Mar 27, 2021 - Abstract #ENDO2021ENDO_3452;
Aggressive thyroid cancer at presentation (AJCC stage, ATA risk category) or during follow-up (distant metastases) is characterized by a circulating immunophenotype comprising of increased immune suppressor cells (regulatory T cells, MDSCs, effector memory T cells) but decreased immune activator cells (CD4+ T cells, gamma delta T cells, NK T-like cells, central memory T cells) as compared to less aggressive thyroid cancer. This circulating immunophenotype may serve as a biomarker for cancer prognosis and guide the selection and development of novel immunotherapies for advanced thyroid cancer.
- |||||||||| Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
[VIRTUAL] SEVERE CHEMOTHERAPY-INDUCED SECRETORY DIARRHEA () - Mar 25, 2021 - Abstract #CDDW2021CDDW_152;
This was a challenging case of CID that did not respond to Loperamide or octreotide and caused a lot of emotional distress for the patient and her providers. Since she responded well to cholestyramine, we recommend its use when the loperamide and octreotide have failed, or in addition to octreotide in severe cases.
- |||||||||| Journal, Myeloid-derived suppressor cells: Phenotyping of Myeloid-Derived Suppressor Cells in Nonhuman Primates. (Pubmed Central) - Mar 25, 2021
Here, using antihuman cross-reactive antibodies, we provide flow cytometric analysis protocols for identification of MDSCs in the blood of rhesus macaques, one of the major NHP species as experimental models. Discrepancies and similarities between rhesus and human MDSCs are discussed.
- |||||||||| Clinical, Journal: An Ig γ Marker Genotype Is a Strong Risk Factor for Alzheimer Disease, Independent of Apolipoprotein E ε4 Genotype. (Pubmed Central) - Mar 23, 2021
The GM 17/17 genotype was associated with a 4-fold increased risk of AD (odds ratio 4.142, p < 0.001). In conclusion, the results of this study demonstrate that Ig GM 17/17 genotype contributes to the risk of later AD development, independent of apolipoprotein ε4 genotype and other AD risk genes, and explain, at least in part, why every HSV1-infected person is not equally likely to develop HSV1-associated AD.
- |||||||||| [VIRTUAL] INMUNE STATUS ON HAEMODIALYSIS PATTIENTS AFFECTED WITH COVID19 INFECTION (Mini-Orals Hall) - Mar 19, 2021 - Abstract #ERAEDTA2021ERA_EDTA_1328;
In conclusion, the results of this study demonstrate that Ig GM 17/17 genotype contributes to the risk of later AD development, independent of apolipoprotein ε4 genotype and other AD risk genes, and explain, at least in part, why every HSV1-infected person is not equally likely to develop HSV1-associated AD. The clinical deterioration on COVID19 infected patients over HD session could be related with monocyte activation and pro-inflammatory cytokines secretion.
- |||||||||| Biomarker, Journal, Tumor microenvironment, BRCA Biomarker, PD(L)-1 Biomarker, IO biomarker: CD200 promotes immunosuppression in the pancreatic tumor microenvironment. (Pubmed Central) - Mar 17, 2021
This needs further investigation. These results indicate that CD200 expression in the PDAC microenvironment may regulate MDSC expansion and that targeting CD200 may enhance activity of checkpoint immunotherapy.
- |||||||||| [VIRTUAL] HumanKIT+myeloid cells facilitate visceral organ colonization by melanoma () - Mar 13, 2021 - Abstract #AACR2021AACR_4854;
Single-cell RNAseq analysis identified a gene signature of a KIT/CD117 expressing CD33+ subset that correlated with decreased overall survival in TCGA melanoma samples. Thus, human CD33+CD11b+CD117+ myeloid cells facilitate metastatic colonization of distant organs by melanoma, representing a novel candidate biomarker as well as a therapeutic opportunity for metastatic melanoma.
- |||||||||| Journal: Multi-omic comparison of Alzheimer's variants in human ESC-derived microglia reveals convergence at APOE. (Pubmed Central) - Mar 12, 2021
AD-associated SORL1 and TREM2 mutations also impaired hMGL Aβ uptake in an APOE-dependent manner in vitro and attenuated Aβ uptake/clearance in mouse AD brain xenotransplants. Using this modeling and analysis platform for human microglia, we provide new insight into epistatic interactions in AD genes and demonstrate convergence of microglial AD genes at the APOE locus.
- |||||||||| [VIRTUAL] Novel breast cancer biomarker in liquid biopsies and its immune regulatory role () - Mar 11, 2021 - Abstract #AACR2021AACR_2378;
In addition, a2NTD treatment was associated with decreased internal staining of Arg-1 in neutrophils and the release of Arg-1 suggesting that a2NTD reprograms neutrophils to have immunosuppressive phenotype. Together, this data shows that a2NTD can be a potential predictor of the growth and metastasis of breast cancer.
- |||||||||| Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca
[VIRTUAL] Identification of a novel immunosuppressive myeloid gene expression signature for clinical biomarker development () - Mar 11, 2021 - Abstract #AACR2021AACR_337;
P1b/2
This led to a 6-gene ‘de novo’ signature (MRC1, APOE, C1QA, C1QB, MMP9, SPP1) associated with IMC function with highly significant concordance (rS = 0.96; p = 1.2e-11) to IMC abundance.Lastly, we showed that in whole blood baseline samples from HNSCC patients (n=53) treated with danvatirsen + durvalumab [NCT02499328], our ‘de novo’ signature was significantly elevated (p=0.033) in patients with progressive disease compared to complete responders. Application to additional studies will be required to more fully determine its clinical utility.
- |||||||||| lecanemab (BAN2401) / Biogen, BioArctic, Eisai, AL003 / Alector, AbbVie, AL-002 / Alector, AbbVie
Review, Journal: A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. (Pubmed Central) - Mar 5, 2021
Robust biomarker-drug codevelopment pipelines are expected to enrich large-scale clinical trials testing new-generation compounds active, directly or indirectly, on neuroinflammatory targets and displaying putative disease-modifying effects: novel NSAIDs, AL002 (anti-TREM2 antibody), anti-Aβ protofibrils (BAN2401), and AL003 (anti-CD33 antibody). As a next step, taking advantage of breakthrough and multimodal techniques coupled with a systems biology approach is the path to pursue for developing individualized therapeutic strategies targeting neuroinflammation under the framework of precision medicine.
- |||||||||| Journal: CD33 and SIGLECL1 Immunoglobulin Superfamily Involved in Dementia. (Pubmed Central) - Mar 2, 2021
The tag SNP association was also analyzed in selected sporadic AD patients from the same Southern Italy region. We demonstrate that CD33 and SIGLECL1 have a significantly increased level of expression in these patients.
- |||||||||| Journal, Myeloid-derived suppressor cells, IO biomarker: Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma. (Pubmed Central) - Feb 26, 2021
Most interestingly, RNAseq of the three subsets revealed that G-MDSCs-related genes were specifically upregulated in mature neutrophils from MM patients vs controls due to differential chromatin accessibility. Taken together, we established a correlation between the clinical significance, immunosuppressive potential and transcriptional network of well-defined neutrophil subsets, providing for the first time, a set of optimal markers (CD11b/CD13/CD16) for accurate monitoring of G-MDCSs in MM.
- |||||||||| Preclinical, Journal, Myeloid-derived suppressor cells, IO biomarker: Human Isogenic Cell Line Models for Neutrophils and Myeloid-Derived Suppressor Cells. (Pubmed Central) - Feb 24, 2021
Lastly, the immunosuppressive activity of the induced MDSCs is inhibited by all-trans retinoic acid and STAT3 inhibitor BP-1-102 through cellular differentiation and dedifferentiation mechanisms, respectively. Together, our study establishes a human isogenic cell line system for neutrophils and MDSCs and this system is expected to facilitate future studies on the biology and therapeutics of human immunosuppressive neutrophils.
- |||||||||| Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Biomarker, Review, Journal: Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment. (Pubmed Central) - Feb 20, 2021
Among them, CD33 expression levels, favorable cytogenetics (t(8;21), inv(16)/t(16;16), t(15;17)) and molecular alterations, such as NPM1, FLT3-internal tandem duplications and other signaling mutations, represent well-known candidates. Additionally, in depth analyses including minimal residual disease monitoring, stemness expression (LSC17 score), mutations or single nucleotide polymorphisms in GO pathway genes (CD33, ABCB1) and molecular-derived scores, such as the recently set up CD33_PGx6_Score, represent promising markers to enhance GO response prediction and improve patient management.
- |||||||||| [VIRTUAL] THE UNIFYING ROLE OF INNATE IMMUNITY IN THE ETIOLOGY AND PATHOGENESIS OF ALZHEIMER'S DISEASE (Plenary) - Feb 19, 2021 - Abstract #ADPD2021ADPD_1592;
Rob Moir and I proposed “The Antimicrobial Protection Hypothesis of Alzheimer’s Disease”, which posits that AD neuropathology comprises an evolutionarily-conserved, orchestrated set of immune responses to protect the brain against infection. Furthermore, we posit that AD-associated genes have been evolutionarily conserved given their ability to bolster the AD neuropathology as an innate immune defense in the brain.
- |||||||||| paclitaxel / Generic mfg.
[VIRTUAL] A Diagnosis I Was Not Expecting - Karamchandani () - Feb 15, 2021 - Abstract #USCAP2021USCAP_626;
Myeloid sarcoma is a tumor mass consisting of myeloid blasts, with or without maturation and presents at an anatomical site other than the bone marrow. 2.
|
